Loading...

CAMP CAMP4 THERAPEUTICS CORP Company Mergers 8-K Filing

CMP4

CMP

CAMP4 THERAPEUTICS CORP

(CAMP)

2025 8-K

New Data Release

Financial Results

Director Appointment

Financial Results Update

Corporate Update

Lease Agreement Update

Stock Offering Update

Collaboration Agreement

Financial Results Announced

Toxicology Studies Initiated

Securities Agreement

Financial Results Announcement

Product Expansion

Financial Statements

Financial Results

Board Appointments

Corporate Presentation

Financial Results

External Links:

On December 17, 2025, Camp4 Therapeutics Corp entered a research and licensing agreement with GSK, receiving an upfront payment of $17.5 million and potential milestone payments of up to $440 million for developing antisense oligonucleotide therapeutics.

AI Assistant

CAMP4 THERAPEUTICS CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.